Fri-08-01-2016, 01:34 AM
Victoria I have been looking and there is a possibility of maybe using the treatment I am on for your son
There is evidence of its use in minors and here is an excerpt of a paper by the NHS
There is evidence of its use in minors and here is an excerpt of a paper by the NHS
Quote:Source.... medicinesresources.nhs.uk/_Fumaderm_for_psoriasis_final.doc
A number of open-label observational studies involving patients aged between 14 and 105 years have been published. A case series involving 14 children aged between eight and 17 years, and a case report of an 11-year old boy have also been published (see Appendix One). These papers provide data on long-term efficacy of FAE, off-label use in children, and use in combination with topical and other systemic agents (concomitant use with other systemic anti-psoriasis agents is not recommended [3]). All patients started on a dose of 105mg daily and, except in one study [22], increased to 1,290mg daily if tolerated. Like the trials above, many do not provide sufficient detail of baseline disease. Three used a recommended combination of outcome measures [23-25], e.g. PASI score and Physician’s Global Assessment (PGA) of improvement (see European Medicines Agency [EMA] guidance [34]), and four studies measured impact on quality of life using a validated scale [24,25,29,31].